The present study provides immunobiochemical and molecular data on the differentiation-linked expression of the bcl-2 proto-oncogene in normal and neoplastic myeloid cells. Using a recently developed monoclonal antibody (MoAb) t o the bcl-2 molecule, staining of normal bone marrow myeloblasts, promyelocytes, and myelocytes, but neither monocytes nor most polymorphonuclear cells, was demonstrated. By two-color flow cytometric analysis, bcl-2 was evidenced in CD33' and CD33+/CD34+ myeloid cells as well as in the more primitive CD33-/CD34+ population. The leukemic cell lines HL-60, KGI, GM-1, and K562 were bcl-2 positive together with ll of 14 acute myeloid leukemias (AML) and three of three chronic myeloid leukemias (CML) in blast crises; six of seven CML were negative. Among myelodysplastic cases, augmentation of the bcl-2 positive myeloblastic compartment was found in refractory anemia with excess of blasts (RAEB) and in transformation (RAEB-t). Western blots HE GENE bcl-2 is involved in the t(14;18) chromo-
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Normal bcl-2 transcripts have been detected in activated but not in resting T-and B-cell lymphocyte^^.^ and in a variety of T-, B-, and pre-B lymphoblastoid cell lines negative for the t( 14;18) chromosomal breakpoint.'.' Moreover, immunohistochemical analysis using recently produced monoclonal antibodies (MoAbs) specific for the human bcl-2 protein7a8 have shown that medullary but not cortical thymocytes and mantle zone but not germinal center B cells of normal lymph nodes are bcl-2 positive. Resting blood T and B lymphocytes also express the protein, despite the reported undetectable levels of mRNA.' Together, these findings indicate that bcl-2 is actively regulated during normal lymphopoiesis. The bcl-2 gene encodes a major nonglycosylated protein of 26 Kd lacking leader or kinase d0mains.4~~~'~ Subcellular fractionation studies have recently established that bcl-2 is an inner mitochondrial membrane protein," the first example of a proto-oncogene with such localization. At present, while the biochemical function of bcl-2 protein is unknown and the reported in vitro GTP-binding activity" has not been c~nfirmed,""~ its physiologic function in blocking programmed cell death or apoptosis is well established. For example, B cells from hyperplastic lymph nodes of bcl-2-Ig transgenic mice possess in vitro a significantly longer survival than normal B cells'4; in addition, deregulated bcl-2 prolongs the survival of growth-factordeprived hematopoietic cell
In this report we present biochemical and molecular data of myeloid leukemias and control lymphocytes extracts evidenced an anti-bcl-2 immunoreactive band of the expected size (26 Kd) . Moreover, the HL-60 and KGI cell lines, both positive for the bcl-2 protein, exhibited the appropriate size bcl-2 mRNA (7.5 Kb). These findings clearly indicate that the bcl-2 gene is operative in myeloid cells and that the anti-bcl-2 MoAb identifies its product and not a crossreactive epitope. Induction of HL-60 differentiation toward the monocytic and granulocytic pathways was accompanied by a marked decrease in bcl-2 mRNA and protein levels; bivariate flow cytometric analysis showed that the fraction becoming bcl-2 negative was in the G1 phase of the cell cycle. These data establish that the bcl-2 proto-oncogene is expressed on myeloid cells and their progenitors and is regulated in a differentiation-linked manner, 0 1992 by The American Society of Hematology.
on the expression of bcl-2 proto-oncogene in normal and malignant myeloid cells, including a population of CD34'/ CD33-hematopoietic progenitor cells.
MATERIALS AND METHODS
Cells, biopsies, and induction of differentiation. The leukemic cell lines KG1 (myeloblastic), HL-60 (promyelocytic), GM-1 (monoblastic), K562 (erythromyeloid), Raji (B lymphoblastic), and the colon carcinoma cell line HT-29, all mycoplasma free, were maintained in RPMI-1640 (Bioproducts Inc, Walkersville, MD) supplemented with 10% heat-inactivated fetal calf serum (Imine Scientific, Santa Ana, CA), 2 mmol/L glutamine, 100 U/mL penicillin, and 100 Fg/mL streptomycin (RPMI-C) in a 5% CO, humidified incubator at 37°C.
Bone marrow aspirates and trephine biopsies from patients with various myeloproliferative disorders were obtained for diagnosis; the latter were fixed in either 10% buffered formalin or Bouin's solution, decalcified overnight in nitric acid or in 10% Titriplex (Merck, Darmstadt, Germany), and embedded in paraffin. Blood samples containing elevated numbers of CD34-positive hematopoietic progenitor cells were obtained from nonhematologic cancer patients undergoing autologous bone marrow transplantation and receiving recombinant human granulocyte-macrophage colonystimulating factor (GM-CSF) after myeloablative chemotherapy. ' The fixation/permeation protocol for optimal immunodetection of bcl-2 internal molecule will be described in detail elsewhere. Briefly, a pellet of lo7 cells was resuspended in 1 mL of 2% Immunocytochemical staining of air-dried paraformaldehydefixed cytospin preparations was performed by the alkalineantialkaline phosphatase (APAAP) techniqueU using a commercial kit (Dakopatts, Glostrup, Denmark); three APAAP repeats Immunocytochemical reactivity of anti-bcl-2 MoAb with normal bone marrow cells. Cytospin preparation of Ficoll-enriched bone marrow aspirate, fixed with 2% paraformaldehyde and permeabilized with 0.001% Triton X100, immunostained by the APAAP methods and counter-stained with Gill's Hematoxylin. In this preparation three myeloid blasts, two late erythroblasts, and a lymphocyte are intensely stained for bcl-2 whereas more mature myeloid cells are negative; some perinuclear staining is also evident (original magnification x 1.000). For personal use only. on October 30, 2017. by guest www.bloodjournal.org From allowed optimal amplification of the reaction. Sections from paraffin-embedded bone marrow specimens were deparaffinized in xylene and graded ethanols, incubated with PBS containing 5% decomplemented human AB serum, and immunostained by the APAAP method; normal mouse serum and an MoAb specific for the leukocyte common antigen CD45 (Dako) were used as negative and positive controls of the APAAP reaction, respectively. Antibcl-2 reactive cells were quantified at 400 X magnification by means of an ocular grid in more than 20 randomly selected fields (equivalent to 2 mm' of tissue). Double-color staining for bcl-2 (green) and DNA (red) was performed on cells that had been previously paraformaldehydefixedlTriton-permeabilized and indirectly labeled for bcl-2 using an FITC-tagged secondary antibody; the cells were then incubated (30 minutes at room temperature) with 1 mglmL RNAse A (Sigma) in PBS and finally in 1 mL of 10 WglmL propidium iodide (Sigma) in PBS.
Flow cytometric analysis of single-and two-color stained samples was performed on an EPICS-C instrument (Coulter Electronics, Hialeah, FL) equipped with a 5-W argon-ion laser set at 488 nm and 5 0 mW output power. Whenever required, color overlaps were eliminated by electronic compensation.
Lysates were prepared by solubilizing 10' cells in 2 mL of a 50 mmol/L Tris buffer solution (TBS) pH 7.5 containing0.5% NP40,1% antagosin. 0.001% phenylmethylsulphonyl fluoride (PMSF); after ultracentrifugation, the supernatants were recovered, boiled for 5 minutes in the presence of 5% B-mercaptwthanol and loaded (50 FLlslot) on 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel, electrophoresed, and blotted onto BA8S nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). After neutralization with 5% BSA in TBS, the membranes were incubated (20 hours at 4°C) with the anti-bcl-2 MoAb (5 )rg/mL) or with an equal amount of normal mouse IgG (for the negative control) diluted in TBS containing 5% BSA and 0.01% NaN3, hence washed extensively with TBS with or without 0.05% Triton XIOO, incubated for 1 hour at room temperature (RT) with '"I-labeled goat antimouse Ig (5 x 10" cpm in 20 mL) (Amersham, Amersham, UK), washed again, and exposed to autoradiographic film.
Poly-A enriched mRNA from treated or untreated cell lines was extracted by a kit (cat. 27-9254-01) purchased from Pharmacia LKB (Uppsala, Sweden). Northern blots were performed as described"; mRNA samples (5 kgllane) were electrophoresed in I % agaroselformaldehyde, transferred onto Duralon UV nylon membranes (Stratagene, La Jolla, CA), and autocrosslinked. Prehybridizations, hybridizations, and washes under stringent conditions were performed as described." The bcl-2 probe was a 1.5-kb Hindlll-EcoRI insert from pFLl obtained from M. Cleary.' One hundred nanograms of the fragment, radiolabeled to a specific activity of 2 to 5 x 10" cpm/pg with "P by the random primer DNA labeling procedure, was used per hybridization.
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RESULTS
bcl-2 positive myeloid cells were found in normal bone marrows as shown by the immunostaining of cytospin preparations (Fig 1) ; 70% of myeloblasts, 83% of promyelocytes, 40% of myelocytes, 12.5% of metamyelocytes, 12.5% of polymorphonuclear cells, and 60% of monoblasts were bcl-2+, whereas monocytes were totally negative. Although the localization of the protein was prcvalcntly cytoplasmic, some perinuclear staining was observed.
The immunofluorescence flow cytometric analysis of bcl-2 in normal bone marrows cvidcnccd 18% 2 5.3% of Detection of bcl-2 protein in myeloid cells. 21 .2% of the CD34' fractions were bcl-2 positive (Fig 2A) . Coexpression of bcl-2 and CD34 was also found in peripheral blood samples from patients trcated with recombinant human (rh) GM-CSF and presenting elevated num- (Fig 2b) .
Immunohistochemical staining of paraffin-embedded normal bone marrow biopsy sections evidenced 14.5% (range 10% to 16%) of anti-bcl-2 reactive nucleated elements, most of which were lymphoid cells and myeloid blasts ( Fig  3A) .
On fresh leukemias the anti-bcl-2 MoAb rcacted with 11 of 14 AML, 1 of 7 CML, and 3 of 3 CML in blast crisis (Table 1) ; no correlation between bcl-2 positivity and French-American-British (FAB) classification was found. Analysis of myelodysplastic syndromes evidcnced a significant increase in bcl-2' blasts in most RAEB and RAEB-t; in some cases clustcrs or nodules of positive cells were observed (Fig 3, B and C) . The number of bcl-2' cells were also augmented in polycythemia vera but not in essential thrombocythemia. To verify that, on myeloid cells, the binding of bcl-2 MoAb was to the bcl-2 gene product rather than to a cross-reactive epitope, further studies at protein and mRNA level were performed.
On Western blots of myeloid leukemia lysatcs the antibcl-2 MoAb identified a protein of identical size (26 Kd) to that of spleen lymphocyte lysates (used here as positive control) and corresponding to bcl-2 (Fig 4) . The 26-Kd protein was also dcmonstrated in the early myelo/ erythroblastic cell line K562; this finding, which suggests that the bcl-2 gene may be expressed by erythroid progenitors, is supported by thc reactivity of the anti-bcl-2 MoAb
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with normal bone marrow erythroblasts (see Fig 1) . Differences in the intensity of the bands indicated that each cell line presented variable amounts of bcl-2 protein that were, among the myeloid leukemias, highest in KG1, albeit lower than in spleen lymphocytes.
Results of Northern blot hybridizations are shown in Fig  5. The bcl-2 specific probe pFLl detected a major mRNA transcript in HL-60 and KG1 of similar size (approximately 7.5 kb) to that found in the B-lymphoblastoid cell line Raji. Strikingly, the KG1 cell line expressed at least 50-fold more mRNA than Raji and this difference did not correspond to a similar augmentation in protein level.
Altogether, the concordance between the immunobiochemical and molecular results indicates that myeloid cells express the bcl-2 proto-oncogene, whose product is recognized by the anti-bcl-2 MoAb.
The pattern of bcl-2 staining in normal bone marrow (BM) myeloid cells is in accord with a differentiation-regulated expression of the bcl-2 gene. The bcl-2 positive promyelocytic cell line HL-60, which can be induced to differentiate along either the granulocytic or monocytic pathway when treated in vitro with specific chemicals,25 provides a suitable model to study this relationship.
Therefore, we have cultured the HL-60 cells in the presence of 1.25% DMSO and 10 ng/mL TPA and monitored at various intervals of time the levels of bcl-2 protein, in relation to other differentiation markers, morphology, and proliferation.
The results are listed in Table 2 . It can be seen that the DMSO-induced granulocytic maturation was accompanied by a progressive decrease in bcl-2 positivity, from greater than 95% in the untreated control to 65% by day 8 (Fig 6) . Similar downregulation of the 26-Kd protein was confirmed by Western blot analysis (Fig 7) . Parallel morphologic changes (eg, increased numbers of cytoplasmic granules and indented nuclei) as well as reduction of the proliferative rate (Fig 6) were observed. As expected, CDllb and CDllc became detectable on a small fraction of cells.z6 Dual-color flow cytometric analysis (Fig 6) showed that most of the bcl-2 negative cells were in the G1 phase of the cell cycle. These cells were, in addition, characterized by a granulocytic morphology (Fig 8) .
The TPA-triggered monocytic/macrophagic differentiation resulted in a rapid decrease in bcl-2 expression (Fig 6) ; within 24 hours the bcl-2 positivity dropped to 55% and by day 5 to about 30%. These changes were also observed on Western blots (Fig 7) . The TPA-induced maturation was evidenced by the strong upregulation of CDllb and CDllc molecules?6 The majority of bcl-2 negative cells were in the G1 phase of the cell cycle.
Downregulation of bcl-2 gene was detected on Northern blots (Fig 5) ; the very faint bands present at day 2 became undetectable by day 5, despite measurable amounts of protein. This finding may actually suggest that the protein has a long half-life. 
DISCUSSION
The bcl-2 proto-oncogene, rearranged and deregulated in B-cell lymphomas carrying the t(14;18) translocation, is expressed in normal and neoplastic cells of the lymphoid lineage negative for the t( 14;18) chromosomal abnormality12,5.6 and the levels of transcription appear to correlate with proliferation and differentiation stage: This relationship has been recently further elucidated by immunohistochemical studies of lymphoid tissues using a newly developed MoAb to bcl-2 gene product,7.R showing strong levels of bcl-2 protein in many normal blood T and B lymphocytes, mantle-zone but not germinal center B cells, in medullary but not cortical thymocytes, and undetectable levels in proliferating lymphoid cells.
AIthough studies regarding the involvement of bcl-2 in human hematopoietic cells have been mostly limited to the lymphoid lineage, bcl-2 is not lineage restricted; indeed, the presence of minimal amounts of transcripts in a monoblastoid cell line2.' and the recent immunodetection of the protein in normal myeloid cells2' suggest that this protooncogene may also play a role in myeloid cell differentiation.
In this report we have provided novel data on the expression of bcl-2 in normal and malignant cells of the myeloid lineage. We based this evidence partly on analysis using an anti-bcl-2 MoAb whose specificity for the 26-Kd protein was confirmed by Western blot of a variety of myloblastic leukemias (including a fresh case). Additionally, we have shown by Northern blot analysis the presence of normal-size bcl-2 transcripts of 7.5 Kb in HL-60 and KG1 cell lines.
To perform quantitative and multiparameter flow cytometric measurements of bcl-2 on single cells, we developed an appropriate fixation/permeabilization procedure for the detection of the protein, localized primarily in the inner mitochondrial and, to a lesser extent, on the perinuclear membrane."
The bcl-2 protein levels among normal myeloid cells are inversely related to maturation; thus, a large fraction of myeloblasts and promyelocytes are bcl-2' whereas metamyelocytes and polymorphonuclear cells are mostly bcl-2 negative, and monocytes totally negative. These findings have been substantiated by two-color flow cytometric analysis showing a large percentage of normal bone marrow bcl-2+ cells expressing CD33, a marker for myeloid cells19 as well as CD34, a marker for myeloid progenitor cells including stem cells.'" Coexpression of bcl-2 and CD34 molecules has been further documented on circulating CD34+ hematopoietic progenitor cells present in blood samples of rhGM-CSF-treated patients. In particular, the bcl-2 protein has been found on CD34+/CD33-/HLA-DR+ cells characterized by low right angle and low forward light TPA DMSO scattering properties; these features are consistent with a progenitor of most of the colony-forming cells in long-term marrow cultures."-m However, further work is needed to determine whether the hematopoietic stem cell is bcl-2'. In view of the fact that bcl-2 protein confers stress resistance to heat shock, ethanol, methotrexate and serum deprivation,I6 and survival,"^" it is attractive to hypothesize that bcl-2 on early hematopoietic progenitor cells, eg, CD33-/ CD34' (?stem cells), favors their long-lived capacity and confers resistance to various external insults. Overall, the pattern of bcl-2 distribution in normal bone marrow myeloid cells appears concordant with the in vitro findings on HL-60, whose differentiation toward the granulocytic and monocytic pathways results in a downregulation of bcl-2 transcription and protein levels. Correlations with cell growth and morphology have shown that the bcl-2 negative cells are mostly in G1 phase of the cell cycle and present features of mature cells.
We have assessed the expression of bcl-2 molecule on fresh myeloproliferative disorders; given that the anti-bcl-2 MoAb reacts with paraffin-embedded tissues, the study was extended to bone marrow biopsies. The results have shown that greater than 70% of AML are bcl-2 positive, whereas most CML are bcl-2 negative.
Increased numbers of bcl-2 positive blasts have been found in myelodysplastic syndromes. No clear-cut correlation between FAB classification and bcl-2 positivity was observed. Overall, it appears that the expression of bcl-2 in myeloid disorders reflects that found in their normal cell counterparts.
The expression of bcl-2 in myeloid leukemias raises the question of its potential prognostic value. In fact, because many anticancer agents also operate through the activation of programmed cell death3' and bcl-2 levels are positively associated with resistance to apoptosis,I6 the possibility exists that bcl-2 positive leukemias are less responsive to chemotherapy than those that are negative. This speculation is now open to investigation.
In conclusion, the data presented here provide the basis for future studies on the role of bcl-2 in myeloid cell commitment, maturation, and survival. 
